• Group revenue grew 2.9% on pcp, with normalised revenue growth of 10.5%
• Underlying EBITDA increased 3.1% on pcp, excluding one-off items
• Solid performance in ANZ and strong growth in Asia region

ParagonCare Limited (ASX: PGC) has reported its 1H26 results, with group revenue growing 2.9% on the prior corresponding period (pcp) to over $1.9 billion. Normalising for the impact of the Infinity Group and COVID-19 drug sales, the company's revenue growth was 10.5%. Underlying EBITDA increased 3.1% on pcp to $49.0 million, excluding one-off items such as the Infinity Group debt provision, integration costs, and M&A expenses. The company's ANZ operations saw solid revenue growth of 2.1% before normalisation, with the Wholesale, Medical Technology, Contract Logistics, and Clinic Manufacturing divisions all contributing. The Asia region delivered strong revenue growth of 33.2%, driven by the Aesthetics business. ParagonCare's balance sheet remains healthy, with net debt of $287.5 million and a net debt to EBITDA ratio of 2.81x on a proforma basis. The company has confirmed its previously announced full-year FY26 guidance, targeting revenue of $3.6-$3.7 billion and underlying EBITDA of $97-$107 million.

ParagonCare confirms its previously announced full-year FY26 guidance, targeting revenue of $3.6-$3.7 billion and underlying EBITDA of $97-$107 million.

ParagonCare continues to execute on its strategic plan, with a growing presence in 9 Asian countries and the finalisation of its 3-2-1 strategy. The company has also been awarded a 5-year Australian Defence Force contract, commencing in Q4FY26.